These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1384 related items for PubMed ID: 24074778

  • 1. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
    Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M.
    Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
    [Abstract] [Full Text] [Related]

  • 2. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J, Perez EA, Pienkowski T, Bell R.
    Oncologist; 2006 Aug; 11 Suppl 1():4-12. PubMed ID: 16971734
    [Abstract] [Full Text] [Related]

  • 3. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
    Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A, PHARE trial investigators.
    Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181
    [Abstract] [Full Text] [Related]

  • 4. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
    Vici P, Viola G, Botti C, Rossi S, Vitucci C, Corsetti S, Di Lauro L, Sergi D, Foggi P, Perri P, Tirelli C, Mottolese M, Fattoruso SI, Lopez M.
    Clin Ter; 2008 Jul; 159(6):449-52. PubMed ID: 19169607
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
    Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, Pienkowski T, Lichinitser M, Semiglazov V, Melichar B, Jackisch C.
    Lancet Oncol; 2012 Sep; 13(9):869-78. PubMed ID: 22884505
    [Abstract] [Full Text] [Related]

  • 7. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    Liberato NL, Marchetti M, Barosi G.
    J Clin Oncol; 2007 Feb 20; 25(6):625-33. PubMed ID: 17308267
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Adjuvant trastuzumab therapy for HER2-positive breast cancer.
    Jahanzeb M.
    Clin Breast Cancer; 2008 Aug 20; 8(4):324-33. PubMed ID: 18757259
    [Abstract] [Full Text] [Related]

  • 12. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).
    de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, Untch M, Smith IE, Gianni L, Baselga J, Jackisch C, Cameron DA, Bell R, Leyland-Jones B, Dowsett M, Gelber RD, Piccart-Gebhart MJ, Suter TM.
    J Clin Oncol; 2014 Jul 10; 32(20):2159-65. PubMed ID: 24912899
    [Abstract] [Full Text] [Related]

  • 13. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY, Turker I, Aksoy S, Oksuzoglu B, Helvaci K, Yildirim Ozdemir N, Uyeturk U, Uysal Sonmez O, Budakoglu B, Zengin N.
    J BUON; 2013 Jul 10; 18(3):585-93. PubMed ID: 24065468
    [Abstract] [Full Text] [Related]

  • 14. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).
    Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, Láng I, Wardley A, Lichinitser M, Sanchez RI, Müller V, Dodwell D, Gelber RD, Piccart-Gebhart MJ, Cameron D.
    Lancet Oncol; 2013 Mar 10; 14(3):244-8. PubMed ID: 23414588
    [Abstract] [Full Text] [Related]

  • 15. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J.
    Lancet; 2010 Jan 30; 375(9712):377-84. PubMed ID: 20113825
    [Abstract] [Full Text] [Related]

  • 16. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
    Kurian AW, Thompson RN, Gaw AF, Arai S, Ortiz R, Garber AM.
    J Clin Oncol; 2007 Feb 20; 25(6):634-41. PubMed ID: 17308268
    [Abstract] [Full Text] [Related]

  • 17. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, Chan S, Wardley A, Greil R, Moore N, Prot S, Pallaud C, Semiglazov V.
    J Clin Oncol; 2013 May 10; 31(14):1719-25. PubMed ID: 23569311
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
    Ward S, Pilgrim H, Hind D.
    Health Technol Assess; 2009 Jun 10; 13 Suppl 1():1-6. PubMed ID: 19567207
    [Abstract] [Full Text] [Related]

  • 20. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.
    Earl H, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Rea D, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mahler-Araujo B, Provenzano E, Chhabra A, Gasson S, Balmer C, Abraham JE, Caldas C, Hall P, Shinkins B, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA.
    Health Technol Assess; 2020 Aug 10; 24(40):1-190. PubMed ID: 32880572
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 70.